A patent review of anticancer CDK2 inhibitors (2017-present)

Area of Science:

• Medicinal Chemistry
• Drug Discovery
• Oncology

Background:

• Cyclin-dependent kinase 2 (CDK2) is crucial for cell cycle progression.
• Overexpression of CDK2 is linked to tumor growth in various cancers.
• The success of CDK4/6 inhibitors fuels research into other CDK inhibitors.

Purpose of the Study:

• To review patent literature on selective CDK2 inhibitors published between 2017 and 2021.
• To identify key developments and challenges in CDK2 inhibitor research.
• To provide insights for medicinal chemists and drug designers.

Main Methods:

• Comprehensive search of patent databases including European Patent Office, American Chemical Society, and Google Patents.
• Analysis of patent literature focusing on selective CDK2 inhibitors.
• Review of inhibitor development efforts by pharmaceutical companies.

Main Results:

• The patent literature from 2017-2021 reveals ongoing efforts in selective CDK2 inhibitor development.
• Challenges in developing selective CDK2 inhibitors persist due to the lack of approved drugs.
• Companies like Incyte Corporation and Pfizer Inc. are actively contributing to this field.

Conclusions:

• Despite challenges, active research in selective CDK2 inhibitors offers promising avenues for cancer therapy.
• The reviewed patent literature provides critical information for advancing CDK2 inhibitor drug design.
• Further development is needed to bring selective CDK2 inhibitors to clinical application.